

UTILITY
PATENT APPLICATION
TRANSMITTAL

Attorney Docket No.

P19977

Total Pages

Inventor(s) or Application Identifier
Takaaki SATO and Shinji IRIE

Title: NADE BINDING PROTEINS

(Only for new nonprovisional applications under 37 CFR 1.53(b))

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

APPLICATION ELEMENTS

ACCOMPANYING APPLICATION PARTS

1. ☒ Fee Transmittal Form
2. ☒ Specification [Total Pages 24]
(preferred arrangement set forth below)
- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure
3. ☐ Drawing(s) (35 USC 113) [Total Sheets]
4. ☒ Oath or Declaration [Total Pages 3]
☐ Newly executed (original or copy) ☒ Unexecuted
☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
[Note Box 5 below]
i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR 1.63(d)(2)
and 1.33(b).
5. ☐ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy
of the oath or declaration is supplied under Box 4b, is considered
as being part of the disclosure of the accompanying application
and is hereby incorporated by reference therein.
6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
a. ☐ Computer Readable Copy
b. ☐ Paper Copy
c. ☐ Statement verifying identity of above copies

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Small Entity Statement(s) ☐ Statement filed in prior application, Status still proper and desired
15. ☐ The prior application is assigned of record to _____
16. ☐ Foreign priority claimed
 - a. ☐ Claim of Priority
 - b. ☐ Certified Copy of Priority Document(s)
17. ☒ Other: Cover Letter under 37 C.F.R. 1.53(b) and (f)

18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior Application No. _____/_____, filed _____

19. ☐ Amend the specification by inserting before the first line the sentence:

This application is a continuation-in-part, continuation, division, of Application No. / , filed

Address all future correspondence to **Customer No. 7055** at the present address of:

GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

9/13/00
Date

Leslie Paperner Reg. No. 33329
Signature

Bruce H. Bernstein, Reg No. 29,027
Typed or Printed Name

FEE TRANSMITTAL

Complete if Known

Application Number	Not Yet Assigned
Filing Date	Concurrently Herewith
First Named Inventor	T. SATO et al.
Group Art Unit	Unknown
Examiner Name	Unknown

TOTAL AMOUNT OF PAYMENT (\$690.00)

Attorney Docket Number P19977

METHOD OF PAYMENT (check one)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 19-0089

Deposit Account Name GREENBLUM & BERNSTEIN, P.L.C.

- ☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17, including any required extension of time fees in any concurrent or future reply requiring a petition for extension of time for its timely submission (37 CFR 1.136(a)(3))
- ☐ Charge the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance, 37 CFR 1.311(b)

2. ☒ Payment Enclosed:

☒ Check ☐ Money Order ☐ Other

FEE CALCULATION (fees effective 11/13/99)

1. FILING FEE

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	690	201	345	Utility filing fee	690
106	310	206	155	Design filing fee	
107	480	207	240	Plant filing fee	
108	690	208	345	Reissue filing fee	
114	150	214	75	Provisional filing fee	

SUBTOTAL (1) (\$) 690

2. CLAIMS

Total Claims	Extra	Fee from below	Fee Paid
6 - 20 =	0	18	0
Independent Claims 2 - 3 =	0	78	0
Multiple Dependent Claims		260	0

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	78	202	39	Independent claims in excess of 3
104	260	204	130	Multiple dependent claim
109	78	209	39	Reissue independent claims over original patent
110	18	210	9	Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0.00

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet.	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	900*	112	900*	Requesting publication of SIR Prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for response within 1st month	
116	380	216	190	Extension for response within 2nd month	
117	870	217	435	Extension for response within 3rd month	
118	1,360	218	680	Extension for response within 4th month	
128	1,850	228	925	Extension for response within 5th month	
119	300	219	150	Notice of Appeal	
120	300	220	150	Filing a brief in support of an appeal	
121	260	221	130	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive unavoidably abandoned application	
141	1,210	241	605	Petition to revive unintentionally abandoned application	
142	1,210	242	605	Utility issue fee (or reissue)	
143	430	243	215	Design issue fee	
144	580	244	290	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of IDS	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	760	246	380	Filing a submission after final rejection (37 CFR 1.129(a))	
149	760	249	380	For each additional invention to be examined (37 CFR 1.129(b))	

Other fee (specify) _____

Other fee (specify) _____

SUBTOTAL (3) (\$) 0.00

*Reduced by Basic Filing Fee paid

SUBMITTED BY

Complete (if applicable)

Typed or Printed Name Bruce H. Bernstein

Reg. Number

29,027

Signature

Leslie J. Paperna Reg. No.

Date

9/13/00

Deposit Account User ID

SPECIFICATION

NADE Binding Proteins

Technical Field

The present invention relates to agents for use in the screening of medicaments for treatment, prevention and/or diagnosis of diseases with cell apoptosis, a method for screening medicaments by using the agents, and medicaments selected by carrying out the screening.

Background Art

Cell death plays an important role in every sort of life phenomenon. In particular, research on cell death in the nervous system is expected as useful to reveal general mechanism of cell death, as well as to develop therapeutic and preventive treatment of diseases relating to the brain and nerve which will presumably be more increasing in the future due to the presently progressing aging society.

The relationship between cell death and information transfer pathway has been being elucidated very recently. Especially as for Fas (CD95), TNF receptors and the like, various molecules have been isolated and identified which participate in information transfer starting from signal receptors of cell death and leading to caspase, a protein that executes cell death.

In nerve cells, information on proliferation and differentiation is transferred through the nerve growth factor (NGF), and it has become apparent recently that NGF induces cell death in some cells. Namely, it has been reported that NGF promotes nerve cell survival through the trkA receptor as a high-affinity receptor, whilst NGF induces cell death in immature nerve cells expressing only p75^{NTR} as a low-affinity NGF receptor and mature neuroglia cells such as oligodendrocyte. p75^{NTR} belongs to the TNF receptor superfamily from a viewpoint of structural feature, and has the death domain in its molecule similarly to TNF receptor. However, as to p75^{NTR}, participation of information transfer protein such as FADD and TRADD has not been reported, and information transfer to apoptosis has not yet been clearly revealed. The nerve growth factor (NGF) acts on cells of the nervous system and induces signals for

cell survival, cell death or cell differentiation. Two receptors, i.e., a high-affinity nerve growth factor receptor (trkA) and a low-affinity one (p75^{NTR}), are known as NGF receptors. However, signal transfer mechanism mediated by p75^{NTR} and molecules participating in the signal transfer have not yet been elucidated sufficiently.

With the progress of study on the signal transfer mechanism mediated by p75^{NTR}, a protein referred to as NADE (p75^{NTR}-associated cell death executor, referred to as "NADE" hereinafter in the specification) was first identified by the research group of Columbia University as a protein which binds to the nerve growth factor receptor (p75^{NTR}) and participates in the induction and regulation of apoptosis (Biol. Chem., 275, pp.17566-17570). It is known that NADE has 124 amino acids in the full length sequence and encodes a protein having the molecular weight of approximately 15 kDa (Hum. Mpl. Genet., 8, 611-619, 1999; reported as Bex3), and that NADE is highly expressed in the brain, heart and lung observed from mRNA level.

As described above, NADE has been elucidated to bind to the nerve growth factor receptor (p75^{NTR}) and participate in the induction and regulation of apoptosis. Identification of a protein which binds to NADE and associates with apoptosis mediated by NADE is expected to be useful for developing medicaments for treatment, prevention and/or diagnosis of apoptosis-associated diseases. However, such proteins have not been identified so far.

Disclosure of the Invention

An object of the present invention is to identify a NADE-binding protein. Another object of the present invention is to elucidate the relationship between the identified NADE-binding protein and apoptosis-associated diseases. Other object of the present invention is to provide a method for screening medicaments for treatment, prevention and/or diagnosis of apoptosis-associated diseases by using the identified NADE-binding protein.

In order to achieve the foregoing objects, the inventors of the present invention first isolated cDNAs of various proteins that bound to NADE by means of the yeast two-hybrid system to clarify signal transfer pathway of apoptosis mediated by p75^{NTR}/NADE. As a result, the inventors successfully identified several interesting proteins including 14-3-3 gene product which is presumed to be an adaptor molecule

participating in the intracellular information transfer, NIK (Nck interacting kinase) and the like, which bind to NADE and are suggested to be involved in apoptosis mediated by p75^{NTR}. The present invention was achieved on the basis of the findings.

According to one aspect of the present invention, there are thus provided agents for use in screening of medicaments for treatment, prevention and/or diagnosis of apoptosis-associated diseases which comprise an apoptosis-related protein which binds to NADE or a DNA encoding said protein.

The apoptosis-related proteins that bind to NADE include, for example, a protein selected from the group consisting of 14-3-3 protein, NIK/HGK protein, P33 ING relative protein, eIF4G protein and Huntingtin-binding protein 1.

According to another aspect of the present invention, there is provided a method for screening medicaments for treatment, prevention and/or diagnosis of apoptosis-associated diseases which comprises the step of detecting interaction between NADE and the apoptosis-related protein which binds to NADE in the presence of a medicament to be tested.

According to a preferred embodiment of the screening method of the present invention, when the tested medicament has an effect on the interaction between NADE and the apoptosis-related protein which binds to NADE, the medicament is chosen as a candidate of an effective medicament.

According to an embodiment of the screening method of the present invention, there is provided a method which comprises the steps of:

- (a) subjecting NADE and the apoptosis-related protein which binds to NADE to interaction with each other in the presence of a medicament to be tested,
- (b) subjecting NADE and the apoptosis-related protein which binds to NADE to interaction with each other in the absence of the medicament to be tested,
- (c) detecting the interactions in the steps (a) and (b), and
- (d) comparing the interactions in the steps (a) and (b), and if the medicament has an effect on said interaction, the medicament is chosen as a candidate of an effective medicament.

According to other aspect of the present invention, there are provided medicaments for treatment, prevention and/or diagnosis of apoptosis-associated diseases which are chosen by the screening method of the present invention.

According to the present invention, it becomes possible to design medicaments controlling apoptosis and develop screening systems for the medicament. It can be expected to develop novel class of medicaments for various nervous diseases caused by abnormal regulation of apoptosis which are not available to date.

Best Mode for Carrying Out the Invention

The agents for use in screening of medicaments for treatment, prevention and/or diagnosis of apoptosis-associated diseases according to the present invention are characterized to comprise an apoptosis-related protein which binds to NADE or a DNA encoding the protein.

The apoptosis-associated diseases herein used include any diseases associated with abnormal apoptosis such as those caused by apoptosis depression or acceleration, and those with depressed or accelerated apoptosis as a result of the disease.

Specific examples of the apoptosis-associated disease include, but not limited thereto, viral diseases such as AIDS, ARC (AIDS associated disease), adult T cell leukemia, ciliary cell leukemia, myelosis, respiratory disorders, arthrosis, HIV or HTLV-1 associated diseases including uveitis, and hepatitis C; cancers; collagen diseases such as systemic lupus erythematosus and chronic rheumatoid arthritis; autoimmune diseases such as ulcerative colitis, Sjogren's syndrome, primary biliary cirrhosis, sudden thrombocytopenic purpura, autoimmune hemolytic anemia, myasthenia gravis, and insulin dependent (type I) diabetes melitus; various diseases with thrombocytopenia such as osteomyelodysplasia syndrome, cyclic thrombocytopenia, aplastic anemia, sudden thrombocytopenia, and disseminated intravascular coagulation; liver diseases of viral or drug hepatitis such as types C, A, B and F, and hepatic cirrhosis; dementia such as Alzheimer's disease and senile dementia of Alzheimer type; cerebrovascular disorders; cardiovascular disorders; nerve degeneration diseases; adult respiratory distress syndrome; infectious diseases; prostatic hypertrophy; uterus myoma; bronchial asthma; arteriosclerosis; various congenital malformation; nephritis; senile cataract; chronic fatigue syndrome; myodystrophy; peripheral nerve disorders; gastrointestinal disorders such as diarrhea and dysentery; eye disorders; obesity; depilation; stress; and ageing. The term "disease" herein used covers a broadest sense including physical and physiologic

conditions such as obesity, depilation, stress and aging.

The apoptosis-associated diseases may be divided more specifically into diseases caused by apoptosis depression and those caused by apoptosis acceleration as follows.

The diseases caused by apoptosis depression include cancers such as follicular lymphoma, cancer caused by variation of p53, breast cancer, ovarian cancer and prostatic cancer; autoimmune diseases such as systemic lupus erythematosus and immunity associated glomerulonephritis; and viral infections such as those caused by herpes virus, adenovirus, and poxvirus. The diseases caused by apoptosis acceleration include AIDS, nerve degeneration diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, pigmentous retinitis and cerebellar degeneration; ischemic diseases such as myocardial infarction and cerebral apoplexy; osteomyelodysplasia diseases such as aplastic anemia; and toxic diseases such as alcoholic hepatitis.

NADE has been reported to bind to the nerve growth factor receptor (p75^{NTR}) and participate in the induction and regulation of apoptosis as described above, and its amino acid sequence and the base sequence encoding the protein are known (Hum. Mpl. Genet., 8, 611-619, 1999; reported as Bex3; its entire disclosure is incorporated herein by reference). NADE protein contains 124 amino acids in its full length and has the molecular weight of approximately 15 kDa. NADE is found to be highly expressed in the brain, heart and lung observed from the mRNA level.

The term "apoptosis-related protein which binds to NADE" herein used means any one of proteins which bind to NADE and participate in apoptosis, which includes unknown as well as known proteins. Preferably, the apoptosis-related protein according to the present invention are proteins whose abnormal interaction with NADE relates in any degree to apoptosis-associated diseases in the intracellular signal transfer pathway via p75^{NTR}/NADE complex.

Specific examples of such apoptosis related protein include, but not limited thereto, the following proteins. References of the proteins will be given in parentheses and all of the disclosures thereof are incorporated herein by reference.

(1) 14-3-3 Protein (Ichimura, T. et al., Proc. Natl. Acad. Sci. USA, 85:7084-7088, 1988; Isobe, T. et al., J. Mol. Biol., 217:125-132, 1991; and Jikken Igaku (Experimental

Medicine) Vol. 13, No. 6 (extra number) 1995, p.120-125, and references therein described).

As functions thereof, those in the intranuclear and extranuclear signal transfer systems have been presumed, which mainly includes control of proliferation and differentiation signals which connect to receptor tyrosine kinases such as EGF (fibroblast growth factor), PDGF (platelet-derived growth factor) and insulin, as well as Ca^{2+} signal control through Ca^{2+} -calmodulin dependent protein kinase II and Ca^{2+} -phospholipid dependent protein kinase as major kinases, and also includes regulations of blood coagulation signals, the H^+ transfer system and transcriptions mediated by Gbox element.

(2) NIK/HGK Protein (Yi-Chi Su et al., The EMBO Journal, Vol. 16, No. 6, pp. 1279-1290, 1997; and Zhengbin Yao et al., The Journal of Biological Chemistry, Vol. 274, No. 4, pp. 2118-2125, 1999)

NIK/HGK functions as an upstream factor MAPKKKK in MAPK cascade to regulate the activity of JNK or P38MAPK through phosphorylation of MEKK and TAK. Recently, different groups have reported that JNK participates in the apoptosis regulation signal mechanism, suggesting that NIK/HGK participates in apoptosis induced by NGF/p75^{NTR}.

(3) P33 ING1 Protein (Moshe Oren, Nature, Vol. 391, p.233-234, 1998; Igor Garkavtseve et al., Nature, Vol. 391, p.295-298, 1998; and Caren C. Helbing et al., Cancer Research 57, 1255-1258, 1997)

P33ING1 is a candidate of a cancer repressor gene. P33ING1 is considered to be one of factors constituting the p53 signal transfer pathway which represses cell proliferation in combination with p53 by controlling activation of p53 dependent transcription. Apoptosis relating to cell cycle may possibly be regulated through ING1.

(4) eIF4G Protein (Imataka, H. et al., EMBO Journal, 16, 817-825, 1997; Yamanaka, S. et al., Genes & Dev., 11: 321-333, 1997; and Jikken Igaku (Experimental Medicine) Vol. 17, No. 7 (May), 1999 and references cited therein)

eIF4G is a translation initiator which binds to proteins connecting to the 3' and 5'-terminals of mRNA (PABP: poly A binding protein, eIF4E: binding to CAP structure) to capture mRNA, and gather ribosomes and lead to translation initiation.

The translation regulation through NADE/eIF4G may possibly control apoptosis.

(5) Huntingtin binding protein 1 (HIP1) (Michael A. Kalchman et al., Nature Genetics, Vol. 16, p.44-p.53, 1997)

This protein is expressed specifically in the cerebrum and cerebellum (no HIP1 protein expression in skeletal muscle, heart, testis, kidney, spleen, liver, and lung), and binds to huntingtin which is a gene product causing Huntington's chorea. HIP1 has homology to Sla2p and Sla2c of yeast *S. cerevisiae* (cytoskeletal-associated protein) and ZK370.3 of *C. elegans*, suggesting that HIP1 participates in apoptosis control through regulation of cytoskeleton formation.

The origins of the apoptosis-related proteins that bind to NADE used in the present invention are not limited, and the proteins may be any proteins such as naturally-derived, recombinant, and chemically synthesized proteins.

The apoptosis-related proteins that bind to NADE used in the present invention may be in the form of those added with a reactive substance, a labeling substance or the like to facilitate subsequent detection steps and the like so that the protein can be suitably used as an agent for screening.

As the agent of the present invention, a DNA encoding the apoptosis-related protein which binds to NADE may be used, in addition to the protein, per se. The apoptosis-related protein is expressed in cells by transfection of a recombinant vector to the cells, which is prepared by ligating a DNA encoding the apoptosis-related protein to a suitable expression vector, and then interaction between the protein thus expressed and NADE can be assayed to screen medicaments for treatment, prevention and/or diagnosis of apoptosis-associated diseases. The expression vector to express a DNA encoding the apoptosis-related protein can be appropriately selected by persons of ordinary skill in the art depending on types of the DNA and the like. In general, the expression vector comprises an appropriate promoter sequence, and if necessary, an appropriate selection marker gene and the like.

The present invention also relates to a method for screening medicaments for treatment, prevention and/or diagnosis of apoptosis-associated diseases which comprises the step of detecting an interaction between NADE and an apoptosis-related protein which binds to NADE in the presence of a medicament to be tested.

The interaction between NADE and the apoptosis related-protein binding to NADE is a protein-protein interaction. Methods for detecting such protein-protein interactions are known in the field, and persons of ordinary skill in the art can appropriately use any method. For example, the following methods can be used.

(1) Coprecipitation (Immune precipitation)

Methods for coprecipitation are known, and an example will be given in Examples of the specification. For example, an agent of the present invention is mixed with NADE in an appropriate solution in the presence of a medicament to be tested in various concentrations to allow interactions with each other, and then the complex of the agent and NADE is subjected to coprecipitation. Then, the precipitate is immunoblotted and then detected using antibodies suitable for detecting the complex (the detection can be made by using anti-NADE antibody and the like as the primary antibody, and the secondary antibody which reacts with the primary antibody), by which effects of the tested medicament on the interaction between NADE and the apoptosis related protein which binds to NADE can be investigated. The effects of the test medicament on the interaction may be either direct or indirect, and their modes are not limited.

(2) ELISA

By fixing the NADE protein on a carrier such as a plate, a nylon filter and a nitrocellulose filter, inhibition or promotion of the binding with the labeled NADE binding protein can be monitored. Alternatively, by fixing the NADE binding protein on a plate, inhibition or promotion of the binding with the labeled NADE protein may be monitored. As the compounds to be screened, chemical libraries and the like can be used.

(3) Application of the yeast two-hybrid system

By simultaneously expressing NADE and the NADE binding protein in yeast and then transducing cDNA or a peptide library to the cells, yeast clones can be screened which have a cDNA effecting the interaction of NADE/the NADE binding protein. A compound of a low molecular weight can be designed in view of the resulting amino acid sequence.

(4) Use of animal cells

By using a reporter gene whose activity in animal cells is easily determined

such as CAT and luciferase, a system (cells) is constructed that has activity when interaction between NADE and the NADE binding protein exists. To the cells, a cDNA, a peptide library, or a low-molecular weight chemical library having high cell membrane permeability is added, and then a substance which effects the interaction of NADE/the NADE binding protein is screened by observing alteration in expression of the reporter gene.

NADE and the apoptosis-related protein which binds to NADE used in the screening method of the present invention may be added to the assay system in the forms of proteins, or supplied to the assay system in the forms of DNAs integrated into expression vectors and the like and expressed in the assay system.

The order to add NADE and the apoptosis-related protein which binds to NADE is not limited, in either way of addition in the forms of proteins or in the forms of DNAs, and they may be added simultaneously or one of them may be added in advance.

The effect of the tested medicament on the interaction between NADE and the apoptosis-related protein which binds to NADE is preferably determined in comparison with a control in which the tested medicament is not added. In addition, it is preferred to investigate whether or not the effects on the interaction change dose dependently by changing amounts of the tested medicament, and to investigate alteration of the effects on the protein-protein interaction with time by a continuous assay.

If the tested medicament has an effect on the interaction between NADE and the apoptosis-related protein which binds to NADE (the effect includes any of advancement or reduction of the interaction, which to be chosen may depend on the type of the apoptosis-related protein used and that of a disease to be treated by the tested medicament), the tested medicament can be chosen as a candidate of an effective medicament. The medicament thus chosen can be subjected to further examinations to verify its efficacy.

The present invention further relates to medicaments for treatment, prevention and/or diagnosis of apoptosis-associated diseases which are selected by the aforementioned screening method.

The types of the medicaments are not particularly limited, and examples

include any types of medicaments such as cytokines, small-molecular medicaments including cell permeable small-molecular medicaments and the like, hormones, combinations of interleukin, lectin and another stimulator, specific antibodies, imitative peptides, antisense oligonucleotides, and other medicaments altering cell functions or protein expression.

The present invention also relates to medicaments for treatment, prevention and/or diagnosis of apoptosis-associated diseases which comprise as an active ingredient a substance controlling intracellular expression or amount of the apoptosis-related protein which binds to NADE. Such medicaments include substances controlling transcription or translation of a gene of the apoptosis-related protein, antisense oligonucleotides of the gene, antibodies recognizing the protein (especially monoclonal antibodies) and the like.

Examples

The present invention will be explained more specifically with reference to the following examples. However, the scope of the present invention is not limited to the following examples.

Example 1: Identification of NADE binding protein molecules by yeast two-hybrid method

Identification of NADE binding protein molecules was performed by yeast two-hybrid method modified by Dr. Stan Horenberg et al. (Cell, 74, 205-214, 1993). In L40 yeast cells (MATa his3 trp1 leu2 ade2 LYZ2::lexA-HIS3 URA3::lexA-lacZ), each of lexA protein having DNA binding ability and VP16 having transcription activating ability does not have transcription activity as a sole. However, the protein complex resulting from the binding between the proteins fusing with each domain induces transcription of reporter genes. That is, only when a fusion target protein of lexA and protein "X" and a fusion protein of VP16 and protein "Y" form a complex through the binding of X and Y, transcription levels of HIS3 and LacZ of reporter genes increase. Yeast cells having the lexA-X fusion protein and the VP16-Y fusion protein, and also having increased transcription of the reporter genes can be selected by observing recovery of a histidine requirement and determining β -galactosidase activity.

By means of this system, screening of a cDNA library derived from 9-days embryo of VP16 fused mice was carried out by using NADE-lexA fusion protein as a target protein.

(1) Transformation of yeast L40 with recombinant vector having NADE gene

A full length NADE gene used for preparation of a recombinant vector was amplified and isolated by the PCR technique using mouse fetal cDNA (Clontech) as a template DNA, and ATGGATCCTCATGGCCAATGTCCACCAGG and ATCTCGAGTCAAGGCATAAGGCAGAATTCATC as primers. The resulting PCR product was treated with restriction enzymes of BamHI and XhoI, and ligated with expression vector pBTM116 which was treated beforehand with restriction enzymes of BamHI and SalI and with SAP to prepare recombinant vector pBTM116-NADE.

Then, yeast L40 cells were transformed by using the recombinant vector pBTM116-NADE. A yeast L40 strain was cultured in 50 ml of YPD medium at 30°C overnight. On the day of transformation, 10 ml of the culture solution was inoculated in 100 ml of YPD medium in a 500 ml flask, and cultured at 30°C for 4 to 6 hours until OD₆₀₀ became 0.3 to 0.5. Then, the culture solution was centrifuged at 3,000 rpm at room temperature for 5 minutes, and the supernatant was removed. The cell pellet was washed with distilled water 3 times and then suspended in 4 ml of 0.1 M lithium acetate/1×TE, and the cells were allowed to stand at room temperature for 10 minutes. The resulting cells were used as competent cells.

The recombinant vector pBTM116-NADE (1 μg) and 100 μg of denatured salmon sperm DNA were placed in an Eppendorf tube and subjected to Vortex mixing. To the resulting mixture, 100 μl of the competent cell solution was added, and the mixture was gently stirred. In addition, 600 μl of 40% PEG3350/0.1 M lithium acetate/1×TE was added to the Eppendorf tube, and the mixture was subjected to Vortex mixing and then allowed to stand at 30°C for 30 minutes. After addition of 70 μl of DMSO and stirring, the mixture was treated at 42°C for 15 minutes with stirring and then cooled. The tube was centrifuged at 15,000 rpm for 5 seconds and the supernatant was removed, and then the cell pellet was suspended in 500 μl of TE.

The cell suspension above was spread over a plate of an essential medium without tryptophan (SD medium) and cultured at 30°C to obtain a transformed cells having the recombinant vector pBTM116-NADE.

Expression of NADE in the transformants was examined in the following manner. The culture solution was first centrifuged at 3,000 rpm at room temperature for 10 minutes, and the pellet was washed with cold distilled water and centrifuged at 3,000 rpm at room temperature for 10 minutes. The pellet was suspended in 1 ml of cool distilled water and transferred into a tube of 1.5 ml, and then centrifuged at 3,000 rpm at 4°C for 5 minutes. To the pellet, two-fold volume (200 μ l) of a complete cracking buffer (8 M urea, 5% SDS, 40 mM Tris-HCl (pH 6.8), 0.1 mM EDTA, 145 mM 2-mercaptoethanol, 1 mM PMSF, 2 μ g/ml aprotinin, 50 μ g/ml leupeptin, 2 mM benzamidine, and 2 μ g/ml pepstatin A) was added, and then the mixture was subjected to Vortex mixing and 150 μ l of beads was added using a spatula. The mixture was allowed to stand at 70°C for 10 minutes and centrifuged at 14,000 rpm at 4°C for 5 minutes, and the supernatant was collected and subjected to SDS-PAGE (12.5% polyacrylamide gel). Western blotting using anti-LexA rabbit polyclonal antibody IgG as the primary antibody verified expression of NADE protein which gave a band in the position of 43 kDa.

(2) Transformation of yeast L40 with cDNA libraries derived from mouse embryo

The yeast L40 having the recombinant vector pBTM116-NADE obtained in (1) above was cultured in 1 L of SD-Trp medium placed in a 3 L flask with a baffle. Cultivation was started at 30°C at the OD₆₀₀ of approximately 0.2, and continued to reach to OD₆₀₀ of 0.4 to 0.6.

The culture solution was transferred into a 50 ml tube and centrifuged at 3,000 rpm at room temperature for 5 minutes. The supernatant was removed, and the cell pellet was washed with distilled water 3 times and suspended in 8 ml of 0.1 M lithium acetate/TE, and then the suspension was allowed to stand at room temperature for 10 minutes. The resulting cells was used as competent cells.

Separately, 100 μ g of a cDNA library derived from mouse 9 day embryo, which was prepared with pVP16 vector (Clontech), and 20 mg (2 ml of 10 mg/ml solution) of denatured salmon sperm DNA were placed in a Falcon tube of 50 ml and well mixed with a Vortex mixer. To the resulting mixture, 8 ml of the competent cell solution was added, and the mixture was gently stirred. In addition, the resulting mixture of the competent cells and the DNA was added to a flask of 500 ml containing 60 ml of 40% PEG3350/0.1 M lithium acetate/TE. The mixture was well mixed, and cultured with

shaking at 30°C for 30 minutes. After addition of 7 ml of DMSO, the mixture was treated at 42°C for 15 minutes (stirred every 5 minutes), and then cooled.

The cell solution was transferred into a tube of 250 ml and centrifuged at 3,000 rpm for 5 minutes, the supernatant was removed, and the cell pellet was washed with 500 ml of sterile distilled water once.

After centrifugation at 3,000 rpm for 5 minutes, the supernatant was removed, and then the cell pellet was suspended in 50 ml of YPD medium and inoculated in 2 flasks of 2 L containing 500 ml of YPD by each 25 ml portions. Cultivation was carried out with shaking at 30°C for 1 hour. After centrifugation at 3,000 rpm at room temperature for 5 minutes, the supernatant was removed, and the cell pellet was washed with the same amount of sterile distilled water 4 times.

The cell pellet was suspended in 4.5 ml of sterile distilled water and spread over plates (150×15 mm) containing 0.5 ml of SD medium (-Trp, -Leu, -His) as 150 μ l portions, and the plates were cultured at 30°C for 3 to 5 days. The cell pellet diluted into appropriate amounts was spread over SD minimal medium (-Trp, -Leu) to determine transformation efficiency. 455 clones in total were isolated as colonies formed. Transformation efficiency was 7.7×10^7 .

(3) β -gal assay

The transformed colony was inoculated by using a toothpick on a nylon membrane placed on a small plate of SD minimal medium (-Trp, -Leu), and cultured at 30°C for 2 to 3 days. The membrane was torn off from the plate and placed on a floater of aluminium foil (about 30 seconds) cooled beforehand with liquid nitrogen, and frozen for 30 seconds. Then the membrane was immersed into liquid nitrogen together with the floater and frozen for 30 seconds. The membrane was taken out from liquid nitrogen using a pincette, and placed on a 3 MM filter paper so as to expose the colonies on the surface and then thawed.

The 3MM filter paper was cut into a round shape so as to fit the size of the small plate, and soaked with 3.2 ml of Z-buffer (60 mM Na_2HPO_4 , 40 mM NaH_2PO_4 , 10 mM KCl, 1 mM MgSO_4) containing 50 μ l of 25 mg/ml X-gal. The thawed membrane was placed on the filter using a pincette so as not to leave air bubbles, and then incubated at 37°C for 30 minutes. After 1, 2, 4, 8 and 24 hours, color development was observed.

As a result, 435 clones with color development were observed in total.

(4) Curing test

In order to remove bait plasmid (pBTM116-NADE) from positive clones of the L40 strain, cultivation was conducted in SD liquid medium (-Leu) for 1 to 2 days, and single colonies were isolated using small plate medium containing the same amino acids. Then, the plate was replicated to SD medium (-Trp, -Leu) to give colonies not growing in -Trp medium.

As a result, 339 clones were isolated in total.

(5) Mating test

Mating was performed between clones losing pBTM116-NADE and having only library plasmid, and yeast for mating (NA87-11A, Mat α leu2 his3 trp1 pho3 pho5) transformed beforehand with pBTM116-NADE, pBTM116-LaminC, pBTM116-CD40, pBTM116-Fas, pBTM116-Ras and pBTM116-TNFR1I, respectively. The yeast clone losing pBTM116-NADE and having only library plasmid was cultured with shaking in SD liquid medium (-Leu), and pBTM116-NADE/NA87-11A, pBTM116-LaminC/NA87-11A, pBTM116-CD40/NA87-11A, pBTM116-Fas/NA87-11A, pBTM116-Ras/NA87-11A, and pBTM116-TNFR1I/NA87-11A were cultured with shaking in SD liquid medium (-Trp), respectively, at 30°C until OD₆₀₀>1.0, and both clones are subjected to mating in 100 μ l of YPD using a 96-well plate at 30°C for 4 to 8 hours.

After the mating, each clone was spotted on SD plates (-Trp, -Leu) by 5 to 10 μ l portions and cultured at 30°C for 2 days. In addition, whether or not the resulting clones express a protein specifically binding to NADE was examined using two reporter genes, His and β -gal.

As a result, a protein specifically binding to NADE was found and 105 clones in total were obtained as those judged to be positive in the His selection and β -gal assay.

Example 2: Structural analysis of NADE binding protein molecules identified by yeast two-hybrid method

As to 96 clones among the positive clones obtained in Example 1, cDNAs derived from the library that the yeast had were collected, and their base sequences

were determined.

The yeast culture solution was first centrifuged at 3,000 rpm for 5 minutes and the supernatant was removed, and then the pellet was suspended in 500 μ l of water and transferred into a tube of 1.5 ml. After centrifugation at 15,000 rpm for 5 seconds, the supernatant was removed. To the residue, 150 μ l of the SZB aqueous solution (1 M sorbitol, 100 mM sodium citrate, 50 mM EDTA, and 8 μ l/ml or 2-mercaptoethanol; further added with 3 mg/ml of ZYMOLYASE (Seikagaku Kogyo; Code12049; Lot No 10971) just before its use) was added, and the mixture was suspended and then allowed to stand at 30°C for 30 minutes with mixing by turning upside down every 5 minutes. The SDS/TE solution (0.1 M Tris-HCl (pH 8.0), 2% SDS) (150 μ g) was added, and the mixture was subjected to Vortex mixing and treated at 65°C for 5 minutes. 5 M potassium acetate (150 μ l) was added, and the mixture was subjected to Vortex mixing and allowed to stand on ice for 30 minutes. After centrifugation at 15,000 rpm at 4°C for 15 minutes, a portion of 300 μ l of the supernatant was transferred into a new tube of 1.5 ml, and then the portion was added with 100 μ l of 10 M ammonium acetate and 1 ml of ethanol and allowed to stand at -20°C for 10 minutes. The operation of further centrifugation and standing was repeated twice, and the pellet was finally washed with 70% ethanol and then dissolved in 30 μ l of water to give a plasmid solution.

The plasmid above was transformed into *E. coli* using electroporation (applying pulses to the mixture of *E. coli* and the plasmid at 1.7 kV, 25 μ F and 200 Ω , and then the cells were cultured at 37°C for 1 hour), and the plasmid was collected from the resulting transformant by alkali method. Using the collected plasmid, the base sequences of the positive clones obtained in Example 1 were determined by a conventional method and compared with the database. As a result of comparison with the database (NCBI's sequence similarity tool), clones having homology to the following base sequences were identified. The numbers in parentheses indicate those of clones obtained.

Mus 14-3-3 eta (1)

mus 14-3-3 beta (1)

Mus 14-3-3 epsilon (4)

NIK (Nck interacting kinase) (4)

Mus EST AA794707 (5)
 Hum Desmoplakin I (3)
 Hum eIF4G (3)
 Mus nuclear autoantigen sperm protein (3)
 hum KIAA 0192 (3)
 Mus M2 type pyruvate kinase (3)
 Hum TSC1 (2)
 Mus laminin B1 (2)
 Mus EST AA499218 (2)
 Hum protein regulating cytokinesis 1(2)
 Mus NADE (1)
 Mus endophilin II (1)
 Hum Huntingtin binding protein 1(HIP1) (1)
 Rat protein tyrosine phosphatase TD14 (1)
 Mus CAG repeat mRNA partial U80888 (1)
 mus TRF1 (1)
 Hum PTAC97 (1)
 Mus putative transcription factor (1)
 Hum rab3-GAP regulatory domain (1)
 Hum Ran GTP B.P. (1)
 Hum RB B.P.II (1)
 Mus ret finger protein 1(REF1) (1)
 Set alpha isoform (1)
 Hum splicing factor SRp55-3 (1)
 Hum SW1/SNF complex 170kD subunit (1)
 Hum tax 1 B.P. (1)
 Mus casein kinase II (1)
 Mus cdr 2 (1)
 Mus fat facets homologue (Fam) (1)
 B.Tra guanine nucleotide exchanging P. (1)
 Mus KIF3 (1)
 Hum Lowe's oculocerebrorenal syndrome (OCRL) (1)

Hum LZTR-1 leucine zipper,ttk DiGeorge (1)
 Mus Mov-34 (1)
 Ratt myosin heavy chain (1)
 Hum EF1 delta leu.zip contain G-nucleotide ex.(1)
 Hum auto antigen (1)
 Rat beta adaptin mRNA, complete cds (1)
 Rat beta spectrin (1)
 Hum DOCK 180 (1)
 Hum Dynactin 50k subunit (1)
 hum EF1 delta (1)
 myotonic dystrophy kinase-related Cdc42-kinase MRCK-beta(1)
 Mus EST AA967322 (1)
 mus EST AU035250 (1)
 Mus EST C85116 (1)
 Mus EST W75029 (1)
 Mus EST (1)
 Mus EST 032345 (1)
 Mus EST AA207590 (1)
 Mus EST AA277260 (1)
 Mus EST AA413882 (1)
 Mus EST AA717789 (1)
 mus EST AA755361 (1)
 Hum KIAA0161 (1)
 Hum KIAA0181 (1)
 Hum KIAA0554/CDC42 B.P. (1)
 Unknown (7)

Among the clones obtained, protein molecules considered to be especially important include the following five proteins. Information of these proteins will be shown below.

(1) 14-3-3 Protein

a) 14-3-3 ϵ (255 amino acids)

Monoisotonic molecular weight = 29,155.4130

b) 14-3-3 β (246 amino acids)

Monoisotonic molecular weight = 28,078.8437

c) 14-3-3 η (246 amino acids)

Monoisotonic molecular weight = 28,194.0212

It is considered that 14-3-3 protein exists as a hetero- or homo-dimer and binds to various proteins as shown below, and that the protein participates in regulation of activity and protein localization.

(Proteins reported to be bound by 14-3-3 protein)

c-Raf-1/A-Raf/Cdc25a/Cdc25b/Cdc25c/PKC-epsilon/PCTAIRE-2/

Tyr hydroxylase/ Tryp hydroxylase/A20/BAD/Cb1/PKC gamma/

IRS-1/BCR/K8kwartin/c-fes

(2) NIK (Nck interacting kinase [mouse]/HGK [human]) (1,233 amino acids)

Molecular weight = 140,515

NIK/HGK functions as an upstream factor MAPKKKK in MAPK cascade to regulate the activity of JNK or P38MAPK through phosphorylation of MEKK and TAK. Recently, different groups have reported that JNK participates in the apoptosis regulation signal mechanism, suggesting that NIK/HGK participates in apoptosis induced by NGF/p75^{NTR}.

(3) P33ING1 (294 amino acids)

Molecular weight = 33,273.84

P33ING1 is a candidate of a cancer repressor gene mapped in 18q34, and highly expressed in aged fibroblasts. Binding to p53 leads to participation in transcription induction of p21WAF1, and high expression induces G1 arrest. Apoptosis relating to cell cycle may possibly be regulated through ING1. The clone obtained was relative to p33ING with homology.

(4) eIF4G Protein (translation initiator) (1,560 amino acids)

eIF4G binds to proteins connecting to the 3' and 5'-terminals of mRNA (PABP: poly A binding protein, eIF4E: binding to CAP structure) to capture mRNA, and gather ribosomes and lead to translation initiation. Translation regulation may possibly control apoptosis through NADE/eIF4G.

(5) Huntingtin binding protein 1 (HIP1) (914 amino acids)

Molecular weight = 102,317.03

This protein is expressed specifically in the cerebrum and cerebellum (no expression of HIP1 protein in skeletal muscle, heart, testis, kidney, spleen, liver, and lung), and binds to huntingtin which is a causal gene product for Huntington's chorea. HIP1 has homology to Sla2p and Sla2c of yeast *S. cerevisiae* (cytoskeletal-associated protein) and ZK370.8 of *C. elegans*, suggesting that HIP1 participates in apoptosis control through regulation of cytoskeleton formation.

Example 3: Binding of NADE protein with 14-3-3 protein *in vivo*

NADE protein expressed in mammal cultured cells was verified to bind to 14-3-3 by an immune precipitation experiment.

To 293T cells derived from human fetal kidney, a mixed solution was added dropwise which was prepared by mixing solution A of expression vector (mNADE/pcDNA3.1(-) Hismycl) containing 500 μ l of OptiMEM and 10 μ l or 1 mg/ml NADEcDNA with solution B of 500 μ l of OptiMEM and 30 μ l of lipofectamine (BRL) and further adding 4 ml of OptiMEM. The mixture was cultured under 5% CO₂ at 37°C for 4 hours. The solution was removed, and 10 ml of complete medium was added. Cultivation was continued under 5% CO₂ at 37°C for transfection of the cells.

After 48 hours from the transfection, the cells were collected and washed twice with 10 ml of PBS and once with 1 ml of PBS. The cells were added with 1 ml of lysis buffer (150 mM NaCl, 1% Triton X100, 20 mM Tris-HCl (pH 7.2), 1 mM EDTA), and centrifuged at 15,000 rpm at 4°C for 30 minutes.

To the protein solution of the cell supernatant obtained above (0.15 ml of 2 mg/ml solution), 1 μ g of anti-NADE antibody and 20 μ l of Protein G Sepharose (Amersham Pharmacia) equilibrated beforehand with lysis buffer were added.

The immune precipitate was separated by performing SDS-PAGE (12.5% polyacrylamide, 200 V, 1 hour) in a conventional manner, and subjected to Western blotting. The resulting membrane was reacted with anti-14-3-3 antibody (Santa Cruz) as the primary antibody, and then with 4,000-fold diluted solutions of horseradish peroxidase-binding goat anti-mouse IgG and horseradish peroxidase-binding goat anti-rabbit IgG (BioRad) as the secondary antibodies, respectively, and then subjected to detection using ECL detection kit (Amersham Pharmacia).

As a result, a specific band was detected in a lane in which anti-14-3-3 antibody was reacted with the immune precipitation fraction of the protein extract which was derived from cells transformed with expression vector containing NADEcDNA.

In a similar manner, by using a cell extract of ES cells (D3) derived from mouse intraembryonic cell aggregate (containing endogenous NADE), protein molecules bound by adding NADE antibody and Protein G Sepharose was subjected to SDS-PAGE and Western blotting in a conventional manner. As the primary antibody, anti-14-3-3 antibody (Sant Cruz) was used, and as the secondary antibodies, 4,000-fold diluted solutions of horseradish peroxidase-binding goat anti-mouse IgG and horseradish peroxidase-binding goat anti-rabbit IgG (BioRad) were used. Detection was made by using ECL detection kit (Amersham Pharmacia). As a result, a specific band was detected.

The aforementioned results showing that 14-3-3/NADE forms a complex in 293T cells and ES cells (D3) indicate that 14-3-3/NADE forms a complex also *in vivo*.

Example 4: Binding of NADE protein with NIK/HGK protein in vivo

NADE protein expressed in mammal cultured cells was revealed to bind to NIK/HGK by an immune precipitation experiment in a similar manner to that in Example 3.

293T cells were cultured overnight, and transformed by calcium chloride method by adding 10 μ g/plate of recombinant vector for NADE expression (pcDNA3.1-NADE-MycHis) and 10 μ g/plate of expression recombinant vector containing full length human NIK (HGK) connected with FLAG. The transformed cells were collected and washed, and a cell extract was prepared. To the cell extract, anti-FLAG antibody (using 1 μ g of antibody per plate of the cell extract) and 20 μ l of Protein G Sepharose (Amersham Pharmacia) were added.

The immune precipitate was separated by performing SDS-PAGE (10% polyacrylamide, 200 V, 1 hour) and subjected to Western blotting to a nylon membrane in a conventional manner. The resulting membrane was soaked in the primary antibody solution (1 μ g/ml of anti-NADE antibody) for the reaction, and after washing, the membrane was then soaked in the secondary antibody solution

(3,000-fold diluted solution of horseradish peroxidase-binding goat anti-rabbit IgG (BioRad)) for the reaction. Detection was made by the ECL method.

As a result, a specific band was detected when detection was made to the immune precipitation fraction of the protein extract, which was derived from cells transformed with expression vector containing NADEcDNA and expression recombinant vector containing full length NIK/HGK connecting to FLAGby, by using anti-NADE antibody as the primary antibody. The results indicate that NIK/NADE forms a complex also *in vivo*.

Example 5: Promotion of the binding of NADE protein with 14-3-3 protein by nerve growth factor (NGF)

It was revealed that the binding of NADE protein with 14-3-3 protein was promoted by nerve growth factor (NGF).

PCNA cells cultured in serum minus medium for 12 hours (70% confluent, 10 cm plate) was collected and suspended in 9 ml of serum minus medium. The cells were added with NGF so as to adjust the final concentration to 10 ng/ml, and incubated for 2 hours. Then, a cell extract was prepared. To the cell extract, anti-NADE antibody (1 μ g of 200 μ g/ml solution) and 10 μ l of Protein G Sepharose (Amersham Pharmacia) were added. The immune precipitate was subjected to SDS-PAGE and Western blotting, and analyzed by using anti-14-3-3 protein antibody as the primary antibody in a similar manner to those in Examples 3 and 4. As a result, 14-3-3 was detected in response to NGF stimulation.

The results indicate that the binding of the 14-3-3/NADE complex is involved in the information transfer system of the NGF/p75^{NTR} complex.

SEQUENCE LISTING

<110> The Institute of Physical and Chemical Research (RIKEN)

<120> NADE Binding Proteins

<130>

<160> 2

<210> 1

<211> 29

<212> DNA

<213> Synthetic DNA

<400> 1

atggatcctc atggccaatg tccaccagg 29

<210> 2

<211> 32

<212> DNA

<213> Synthetic DNA

<400> 2

atctcgagtc aaggcataag gcagaattca tc 32

What is claimed is:

1. An agent for use in screening of a medicament for treatment, prevention and/or diagnosis of an apoptosis-associated disease which comprises an apoptosis related protein which binds to NADE (p75^{NTR}-associated cell death executor) or a DNA encoding said protein.

2. The agent according to claim 1, wherein the apoptosis related protein binding to NADE is a protein selected from the group consisting of 14-3-3 protein, NIK/HGK protein, P33 ING relative protein, eIF4G protein and Huntingtin-binding protein 1.

3. A method for screening a medicament for treatment, prevention and/or diagnosis of an apoptosis-associated disease which comprises the step of detecting interaction between NADE and an apoptosis related protein which binds to NADE in the presence of a medicament to be tested.

4. The method according to claim 3, wherein the medicament tested is selected as a candidate of an effective medicament when the medicament has an effect on the interaction between NADE and an apoptosis related protein which binds to NADE.

5. The method according to claim 3, which comprises the steps of:
(a) subjecting NADE and the apoptosis related protein which binds to NADE to interaction with each other in the presence of the medicament to be tested,
(b) subjecting NADE and the apoptosis related protein which binds to NADE to interaction with each other in the absence of the medicament to be tested;
(c) detecting the interactions in the steps (a) and (b), and
(d) comparing the interactions in the steps (a) and (b) to choose the medicament having an effect on the interaction as a candidate of an effective medicament.

6. A medicament for treatment, prevention and/or diagnosis of an apoptosis-associated disease which is chosen by the method of claim 3.

ABSTRACT

Agents for use in screening of medicaments for treatment, prevention and/or diagnosis of apoptosis-associated diseases are provided which comprise an apoptosis related protein binding to NADE (p75^{NTR}-associated cell death executor) or a DNA encoding said protein.

Declaration and Power of Attorney For Utility or Design Patent Application

特許出願宣言書

Japanese Language Declaration

私は、下欄に氏名を記載した発明者として、以下のとおり
宣言する：

私の住所、郵便の宛先および国籍は、下欄に氏名に続いて記載したとおり
であり、

名称の発明に関し、請求の範囲に記載した特許を求める主題の本来の、
最初にして唯一の発明者である(一人の氏名のみが下欄に記載されている
場合)か、もしくは本来の、最初にして共同の発明者である(複数の氏名が
下欄に記載されている場合)と信じ、

上記発明の明細書(下記の欄でX印がついていない場合は、
本書に添付)は、

☐ 年 月 日に提出され、

米国出願番号 _____ とし、

(該当する場合) 年 月 日に訂正されました。又は、

特許協定条約国際出願番号 _____ とし、

(該当する場合) 年 月 日に訂正されました。

私は、前記のとおり補正した請求の範囲を含む前記明細書の内容を検討
理解したことを陳述する。

私は、連邦規則法典第37編第1条第56項に定義されるとおり、特許資
格の有無について重要な情報を開示すべき義務があることを認めます。

私は合衆国法典第35部第119条(a-d)項又は第365条(b)項に基づく、下
記の外国特許出願又は発明者証出願、或いは第365条(a)項に基づく、少な
くとも米国以外の1ヶ国を指名したPCT国際出願の外国優先権を主張し、
更に優先権の主張に係わる基礎出願の出願日前の出願日を有する外国特許
出願、又は発明者証出願或いはPCT国際出願を以下に“なし”の箱に印を
つけることにより明記する：

Prior foreign applications

先の外国出願

260947/1999

(Number)
(番号)

Japan

(Country)
(国名)

14/September/1999

(Day/Month/Year Filed)
(出願の年月日)

(Number)
(番号)

(Country)
(国名)

(Day/Month/Year Filed)
(出願の年月日)

☐ その他の外国特許出願番号は別紙の追補優先権欄にて記載する。

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated
below next to my name.

I believe I am the original, first and sole inventor (if only one name is
listed below) or an original, first and joint inventor (if plural names
are listed below) of the subject matter which is claimed and for
which a patent is sought on the invention entitled

NADE Binding Proteins

the specification of which is attached hereto unless the following
box is checked:

☐ was filed on _____ as

United States Application Number _____

and was amended on _____ (if applicable) or,

PCT International Application Number _____

and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents
of the above identified specification, including the claims, as
amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to
patentability as defined in Title 37, Code of Federal Regulations,
§1.56.

I hereby claim foreign priority under Title 35, United States Code
§119(a-d) or §365(b) of any foreign application(s) for patent or
inventor's certificate, or §365(a) of any PCT international application
which designated at least one country other than the United States,
listed below. I have also identified below, by checking the "No"
box, any foreign application for patent or inventor's certificate, or of
any PCT international application having a filing date before that of
the application on which priority is claimed:

Priority claimed
優先権の主張

☒

Yes

あり

☐

Yes

あり

☐

No

なし

☐

No

なし

☐ Additional foreign application numbers are listed on a
supplemental priority sheet attached hereto.

Japanese Language Utility or Design Patent Application Declaration

私は、合衆国法典第35部第119条(e)項に基づく、下記の合衆国仮特許出願の利益を主張する。

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

(Application No.)
(出願番号)

(Day/Month/Year Filed)
出願の年月日

(Application No.)
(出願番号)

(Day/Month/Year Filed)
出願の年月日

(Application No.)
(出願番号)

(Day/Month/Year Filed)
出願の年月日

☐ その他の合衆国仮特許出願番号は別紙の追補優先権欄にて記載する。

☐ Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

私は、合衆国法典第35部第120条に基づく下記の合衆国特許出願、又は第365条(c)項に基づく合衆国を指名したPCT国際出願の利益を主張し、本願の請求の範囲各項に記載の主題が合衆国法典第35部第112条第1項規定の態様で、先の合衆国特許出願又はPCT国際出願に開示されていない限度において、先の出願の出願日と本願の国内出願日又はPCT国際出願日の間に有効となった連邦規則法典第37部第1章第56条に記載の特許要件に所要の情報を開示すべき義務を有することを認める。

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or §365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

(Application No.)
(出願番号)

(Day/Month/Year Filed)
(出願の年月日)

(現況)
(特許済み、係属中 放棄済み)

(Status)
(patented, pending, abandoned)

(Application No.)
(出願番号)

(Day/Month/Year Filed)
(出願の年月日)

(現況)
(特許済み、係属中 放棄済み)

(Status)
(patented, pending, abandoned)

☐ その他の合衆国又は国際特許出願番号は別紙の追補優先権欄にて記載する。

☐ Additional U.S. or international application numbers are listed on a supplemental priority sheet attached hereto.

私は、ここに自己の知識にもとずいて行った陳述がすべて真実であり、自己の有する情報および信ずるところに従って行った陳述が真実であると信じ、さらに故意に虚偽の陳述等を行った場合、合衆国法典第18部第1001条により、罰金もしくは禁錮に処せられるか、またはこれらの刑が併科され、またかかる故意による虚偽による陳述が本願ないし本願に対して付与される特許の有効性を損なうことがあることを認識して、以上の陳述を行ったことを宣言する。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

私、下記署名者は、ここに記載の米国弁護士または代理人に本出願に関し特許商標庁にて取られるいかなる行為に関して、同米国弁護士又は代理人が、私に直接連絡なしに私の外国弁護士或いは法人代表者からの指示を受け取り、それに従うようここに委任する。この指示を出す者が変更の場合には、ここに記載の米国弁護士又は代理人にその旨通知される。

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from either his foreign patent agent or corporate representative, if any, as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

Japanese Language Utility or Design Patent Application Declaration

委任状： 私は、下記発明者として、下記に明記された顧客番号を伴う以下の弁護士又は、代理人をここに選任し、本順の手続きを遂行すること並びにこれに関する一切の行為を特許商標庁に対して行うことを委任する。そして全ての通信はこの顧客番号宛に発送される。

顧客番号 7055

現在選任された弁護士は下記の通りである。

Neil F. Greenblum Reg. No. 28,394
Bruce H. Bernstein Reg. No. 29,027
James L. Rowland Reg. No. 32,674
Arnold Turk Reg. No. 33,094

POWER OF ATTORNEY: As a named inventor, I hereby appoint the attorney(s) and/or agent(s) associated with the Customer Number provided below to prosecute this application and transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

CUSTOMER NUMBER 7055

The appointed attorneys presently include:

Stephen M. Roylance Reg. No. 31,296
William E. Lyddane Reg. No. 41,568
William Pieprz Reg. No. 33,630
Leslie J. Paperner Reg. No. 33,329

Address: **GREENBLUM & BERNSTEIN, P.L.C.**

1941 ROLAND CLARKE PLACE
RESTON, VA 20191

直接電話連絡先：(名称および電話番号)

Direct Telephone Calls to: (name and telephone number)

GREENBLUM & BERNSTEIN, P.L.C.

(703) 716-1191

唯一のまたは第一の発明者の氏名	Full name of sole or first inventor Takaaki SATO
同発明者の署名 日付	Inventor's signature Date
住所	Residence Tokyo, Japan
国籍	Citizenship Japan
郵便の宛先	Post Office Address 2-1-1-303, Nakaikegami, Oota-ku, Tokyo 146-0081, Japan
第2の共同発明者の氏名 (該当する場合)	Full name of second joint inventor, if any Shinji IRIE
同第2共同発明者の署名 日付	Second Inventor's signature Date
住所	Residence Ibaraki, Japan
国籍	Citizenship Japan
郵便の宛先	Post Office Address 2-41-15, Kamiya, Ushiku-shi, Ibaraki 300-1216, Japan

(第六またはそれ以降の共同発明者に対しても同様な情報および署名を提供すること。)

(Supply similar information and signature for third and subsequent joint inventors.)